论文部分内容阅读
大多数弥漫性大细胞淋巴瘤(DLCL)患者经化疗后可获完全缓解(CR),但其中至少1/3最终复发,常见于CR后2年内,且补救治疗的结果一般极差,故早期识别CR后复发的高危患者对于选用新的后补性治疗措施尤显重要。为分析处于CR的DLCL忠者的复发风险和复发类型(早期、后期复发)。作者调研了按REAL分类标准诊断为DLCL的103例患者(男53例,女50例,中数年龄55岁),53％发现1处结外侵犯,7％发现≥2处结外侵犯,44％处于Ann ArborⅢ-Ⅳ期,采用含阿霉素的一线联合方案治疗全部获得CR。CR后2年以内复发为早期复发,
Most patients with diffuse large cell lymphoma (DLCL) can achieve complete remission (CR) after chemotherapy, but at least one-third of them eventually relapse, usually within 2 years after CR, and the results of remedial treatment are generally very poor, so early Identifying high-risk patients who have relapsed after CR is particularly important for the selection of new follow-up measures. To analyze the risk of relapse and the type of relapse (early and late relapse) of DLCL loyalty in CR. The authors investigated 103 patients diagnosed as DLCL according to the REAL classification criteria (53 males and 50 females, median age 55 years), 53% found one extranodal infringement, and 7% found ≥ 2 extranodal invasives, 44 % is in Ann Arbor III-IV and all patients received CR with a first-line combination regimen containing doxorubicin. Relapse within 2 years after CR is an early relapse,